IE 11 is a very old browser and is not supported on this site.



Galenica continues to grow in financial year 2023: The Galenica Group grew strongly with an increase in sales of 4.4% in financial year 2023 and generated consolidated net sales of CHF 3,746.0 million. Adjusted for the extraordinary sales in connection with COVID-19 (self-tests, COVID-19 vaccinations and rapid tests) in the prior-year period, growth amounted to a high 5.0%.

Highlights of the 2023 financial year

Consultations and services


+14% compared to previous year



in Galenica Group pharmacies

Employee survey


Satisfaction and motivation score among employees of the Galenica Group

Adjusted1 EBIT increased by 0.4% to CHF 191.3 million, despite special factors in the amount of CHF 9.8 million. Without these special factors, adjusted1 EBIT would have in-creased by 5.5% to CHF 201.1 million. Thanks to this solid result, the Board of Directors will propose to the Annual General Meeting a dividend at the previous year’s level (CHF 2.20 per share).

Highlights of the 2023 financial year

  • Around 138,000 customers made use of the healthcare services and consultations offered by Galenica pharmacies in 2023, 14% more than in the previous year.
  • Compared to the previous year, demand for vaccinations in Galenica pharmacies increased by 18% (excluding COVID-19 vaccinations).
  • Together with Redcare Pharmacy, Galenica established Switzerland’s leading online pharmacy, adding a pure only pharmacy to its offering.
  • After more than three years of renovation work, the Amavita Bahnhof Apotheke opened its new retail premises at Zurich’s main station in November 2023.
  • With the acquisition of Padma, Verfora further expanded its complementary medicine offering, thereby increasing its overall market share in the Swiss consumer healthcare market to 10.3%.
  • The home care offerings in the Galenica network, in particular those of Lifestage Solutions, Bichsel and Medifilm, were linked more closely in the year under review and performed very successfully, with demand significantly higher than in the previous year.
  • Galexis actively contributed to improving security of supply of medicines in Switzerland through its “Safety Stock” initiative.
  • The Documedis® medical and pharmacy software was technically further developed in the reporting year. In 2023, over 270 million "Clinical Decision Support Checks" (CDS) were carried out on the basis of Documedis® solutions, 145% more than in the previous year.

1) Excluding the effects of IAS 19 and IFRS 16. See chapter “Alternative performance measures”.

Galenica uses cookies to optimise the functions of the website and to ensure you enjoy the best possible experience. Use of cookies & disclaimer